维持依维莫司联合减量环孢素的肾移植受者癌症风险可能降低
该研究基于A2309试验亚组95例肾移植受者,比较依维莫司联合减量环孢素与麦考酚钠联合标准剂量环孢素随访7年的癌症发生风险。依维莫司组非黑色素瘤皮肤癌、非皮肤癌及任何癌症的未调整风险比分别为0.28、0.39和0.41,调整后分别为0.34、0.35和0.32。两组排斥反应、移植物丢失或死亡无差异。作者认为依维莫司联合减量环孢素可能降低癌症风险,尤其非黑色素瘤皮肤癌,但需更大队列证实。
要点
- 依维莫司联合减量环孢素与任何癌症风险降低相关,调整后HR 0.32(95%CI 0.15-0.71)。
- 非黑色素瘤皮肤癌风险亦降低,调整后HR 0.34(95%CI 0.13-0.91)。
- 两组排斥反应、移植物丢失或死亡无关联。
核心结论
- 与标准剂量环孢素相比,依维莫司联合减量环孢素可能降低癌症风险,尤其非黑色素瘤皮肤癌;若更大队列证实,初始使用依维莫司联合减量钙调磷酸酶抑制剂或可减少移植后癌症负担。
研究设计与样本
- 基于澳大利亚和新西兰透析与移植登记处(ANZDATA)数据,对曾参与A2309研究的肾移植受者亚组进行7年随访分析,采用调整Cox比例风险模型。
- 共95例受者,66例随机分配至依维莫司(1.5 mg或3 mg)联合减量环孢素组,29例接受麦考酚钠联合标准剂量环孢素组。
主要发现
- 依维莫司组 vs 麦考酚钠联合标准剂量环孢素组:非黑色素瘤皮肤癌未调整HR 0.28(95%CI 0.11-0.74),非皮肤癌未调整HR 0.39(95%CI 0.16-0.98),任何癌症未调整HR 0.41(95%CI 0.23-0.71)。
- 调整后HR分别为:非黑色素瘤皮肤癌0.34(95%CI 0.13-0.91),非皮肤癌0.35(95%CI 0.09-1.25),任何癌症0.32(95%CI 0.15-0.71)。
- 治疗分组与排斥反应、移植物丢失或死亡之间无关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需在更大队列中证实上述结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Kidney transplant recipients are at a high risk of developing cancers after transplantation. Switching from calcineurin inhibitors to sirolimus has been shown to prevent secondary nonmelanoma skin cancer but whether everolimus with reduced exposure to calcineurin inhibitors has similar anti-cancer effects remains unknown. Therefore, we compared the risk of incident cancer over seven years of follow-up among kidney transplant recipients randomized to everolimus plus reduced exposure cyclosporine versus mycophenolate sodium and standard exposure cyclosporine. Using the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA), we assessed the seven-year risk of incident cancer and other graft outcomes among a subgroup of recipients who had participated in the A2309 study using adjusted Cox proportional hazard models. Of 95 recipients, 66 were randomized to everolimus (1.5 mg or 3 mg) with reduced cyclosporine and 29 received mycophenolate sodium and standard exposure cyclosporine. Compared to mycophenolate sodium and standard exposure cyclosporine, everolimus treatment was associated with unadjusted hazard ratios of 0.28 (95% confidence interval 0.11-0.74), 0.39 (0.16-0.98) and 0.41 (0.23-0.71), respectively for nonmelanoma skin cancer, non-skin cancers and any cancers. Interestingly, the adjusted hazard ratios were 0.34 (0.13-0.91), 0.35 (0.09-1.25) and 0.32 (0.15-0.71), respectively. There was no association between treatment groups and rejection, graft loss or death. Compared to standard-exposure cyclosporine, everolimus with reduced exposure to cyclosporine may be associated with a reduced risk of cancer, particularly for non-melanoma skin cancer. Thus, if confirmed in larger patient cohorts, de novo use of everolimus with reduced exposure to calcineurin inhibitors may enable a reduction in cancer burden after transplantation.
引用
- Lim WH, Russ GR, Wong G, et al. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine. Kidney Int. 2017. PMID: 28109543. doi:10.1016/j.kint.2016.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。